Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
about
Pharmacologic resistance in colorectal cancer: a reviewTherapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesCETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.Role of Akt signaling in resistance to DNA-targeted therapyDrugging the addict: non-oncogene addiction as a target for cancer therapyMetabolic pathways promoting cancer cell survival and growthOxidative Stress and Response to Thymidylate Synthase-Targeted AntimetabolitesCeramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent MannerPhase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma.Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous RecombinationAssociation between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysisThe effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustrationDetection of uracil within DNA using a sensitive labeling method for in vitro and cellular applications.Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer ProgramPre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression.FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Emerging drugs in refractory colorectal cancer.TAS-102, a novel antitumor agent: a review of the mechanism of action.P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.The druggability of intracellular nucleotide-degrading enzymes.TAS-102: a novel antimetabolite for the 21st century.Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Early Perspective.The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: clinical and occupational implications.Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.Targeting of Helicobacter pylori thymidylate synthase ThyX by non-mitotoxic hydroxy-naphthoquinoneslncRNA HOTAIR Contributes to 5FU Resistance through Suppressing miR-218 and Activating NF-κB/TS Signaling in Colorectal Cancer.dUTPase inhibition augments replication defects of 5-Fluorouracil.Activation of Two Sequential H-transfers in the Thymidylate Synthase Catalyzed Reaction.
P2860
Q26769850-2BCD1089-43CD-45B6-9F32-EB4E6E7D61D4Q26777679-0C264C91-D683-4D64-9D88-CFA06ED99CA6Q27323225-D5A64B8E-F3A6-4990-B696-2B3A6961BD16Q28066950-3CDAC324-1E7A-4623-9DBD-AB2B588C871AQ28079559-80A52E9E-4626-4510-A880-A1D06236C148Q28086940-41491E85-D060-47EB-8B52-893A7F2F24DCQ28394674-C13AF95F-E098-4C97-9C09-C7CA10696DFCQ28552611-EA098F9B-4104-4E63-8BC1-D776AA8754D6Q33167150-3078D470-2AE9-4CFC-8130-1CF95E134C69Q36161868-03571F04-3681-438E-96C6-A6798BC2F4C2Q36432422-1FD0C425-337F-43C0-B174-D05CDA5D5AAEQ36473730-ECFD14D4-78E1-4D61-8DC9-02AC3EBC1E1DQ36489483-7027E390-E41D-4730-BF6F-333252CABA99Q36588979-4CFF0438-EBDF-4529-A9D8-6AC290AA40CDQ36893736-0A5E67EC-6597-48FB-ACAA-4A9ED3045CDDQ37190389-AD157D8A-36F2-4B33-AFB7-1871E08332D8Q37258328-59488442-D8D6-4D81-B9D1-507D82D44FBBQ37702756-370FB952-D3FE-4B8C-8AF7-DF96A995F66DQ37703201-50F05E19-6FC8-4F63-8070-D64C92CF9D73Q37706861-7454351D-0831-446B-9B56-58340479C555Q38373831-AF499E33-C85F-4A31-AF23-BFA434DBB12EQ38570584-8C324522-9E0B-4AE5-9097-7059D515B3BFQ38597310-64BFDEF3-414C-428F-867E-56281B8B05A6Q38603038-5BB1A66B-D707-4719-8B36-15F9C86B84F1Q38650970-E64271EC-96F1-4D3B-87B7-76F157CB5F02Q38652269-CB4012C8-A4C7-4305-8DDC-E6E0EF85DD8CQ38713930-BDCA5810-1FF6-4871-A854-43971ED475B6Q38792334-139ED970-70E3-49A3-97CC-36ACFBAC2AE5Q38794338-C67C4692-8E06-4E55-A20C-77144C59612DQ38843033-0ABBB91F-697F-4FC1-A011-1CEB299B9F6CQ38856091-3CEE8372-8A9F-4008-BD12-9B4A3603E30BQ38906680-C0A627D1-B05C-4EFC-9A0A-D2BDFA52B635Q39153086-447C45D5-03FE-4565-BC2C-BBD706FA6526Q40468248-95EB904C-B339-4626-BA34-3AECB37225D6Q40786849-FBE9AB27-009A-4402-9380-D93E54B5DB11Q41009634-7AB77123-11C8-4F69-938C-9AF554E53568Q41187011-EBCB3DA2-6E2B-4FFF-8BC2-3CC943DD92D2Q41191235-E0ECA8FD-4B76-4229-A8E8-B4DD3214FE11Q41767730-CFCBE230-D4DB-4F7B-949E-4D5FC1539FC5Q41873965-D6C02ADF-BA54-4BDA-BBF8-28BF758B8A62
P2860
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
@en
type
label
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
@en
prefLabel
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
@en
P2093
P2860
P1476
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
@en
P2093
Patrick G Johnston
Peter M Wilson
Peter V Danenberg
Robert D Ladner
P2860
P304
P356
10.1038/NRCLINONC.2014.51
P407
P577
2014-04-15T00:00:00Z